Pichlmair Andreas, Pollak Matthias, Bergthaler Andreas
Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Freiburg, Deutschland.
Berl Munch Tierarztl Wochenschr. 2004 Jul-Aug;117(7-8):252-65.
The interferon system is part of the innate immune system in vertebrates. It represents the first line of host defence against viral infections. Virus entry triggers intracellular signalling pathways which lead to the secretion of soluble factors such as interferons and other cytokines. Interferons signal to neighbouring cells that a viral infection has occurred and induce an "antiviral state" resulting in inhibition of virus replication. The first recombinant interferons were produced in the 1980ies and were considered to be a major breakthrough. At present, interferons are routinely used in the therapy of certain viral and autoimmune diseases as well as for neoplastic disorders in man. In 2001 the first interferon preparation for veterinary use was licensed in the European Union. This review summarises the molecular mechanisms of the interferon system and the viral counteractions. The current type I interferon therapies in humans are described and an overview of recent clinical studies in veterinary medicine, including cat, dog, horse, cow, sheep, pig, and poultry, is given. We review the potential application of interferons and arguments in favor or against its therapeutic use in veterinary medicine.
干扰素系统是脊椎动物固有免疫系统的一部分。它是宿主抵御病毒感染的第一道防线。病毒进入会触发细胞内信号通路,从而导致可溶性因子如干扰素和其他细胞因子的分泌。干扰素向邻近细胞发出病毒感染已发生的信号,并诱导“抗病毒状态”,从而抑制病毒复制。首批重组干扰素于20世纪80年代生产,被认为是一项重大突破。目前,干扰素常规用于治疗某些病毒和自身免疫性疾病以及人类的肿瘤性疾病。2001年,第一种兽用干扰素制剂在欧盟获得许可。本综述总结了干扰素系统的分子机制和病毒的对抗作用。描述了目前人类的I型干扰素疗法,并概述了近期在兽医学中的临床研究,包括猫、狗、马、牛、羊、猪和家禽。我们回顾了干扰素的潜在应用以及支持或反对其在兽医学中治疗用途的观点。